BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 25794689)

  • 1. Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone.
    Achiam MP; Jensen LB; Larsson H; Jensen LS; Larsen AC; Holm J; Svendsen LB
    Scand J Surg; 2016 Mar; 105(1):22-8. PubMed ID: 25794689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
    Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
    Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysphagia is not a Valuable Indicator of Tumor Response after Preoperative Chemotherapy for R0 Resected Patients with Adenocarcinoma of the Gastroesophageal Junction.
    Strandby RB; Svendsen LB; Bæksgaard L; Egeland C; Achiam MP
    Scand J Surg; 2016 Jun; 105(2):97-103. PubMed ID: 26250355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
    van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
    Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Body Mass Index on Complications and Survival after Surgery for Esophageal and Gastro-Esophageal-Junction Cancer.
    Kruhlikava I; Kirkegård J; Mortensen FV; Kjær DW
    Scand J Surg; 2017 Dec; 106(4):305-310. PubMed ID: 28737095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
    Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study.
    Papaxoinis G; Kamposioras K; Weaver JMJ; Kordatou Z; Stamatopoulou S; Germetaki T; Nasralla M; Owen-Holt V; Anthoney A; Mansoor W
    J Gastrointest Surg; 2019 Sep; 23(9):1729-1741. PubMed ID: 30671799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
    Mingol F; Gallego J; Orduña A; Martinez-Blasco A; Sola-Vera J; Moya P; Morcillo MA; Ruiz JA; Calpena R; Lacueva FJ
    BMC Surg; 2015 May; 15():66. PubMed ID: 25997454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer of the gastroesophageal junction: combined modality therapy.
    Ilson DH
    Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
    Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
    J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    Cunningham D; Allum WH; Stenning SP; Thompson JN; Van de Velde CJ; Nicolson M; Scarffe JH; Lofts FJ; Falk SJ; Iveson TJ; Smith DB; Langley RE; Verma M; Weeden S; Chua YJ; MAGIC Trial Participants
    N Engl J Med; 2006 Jul; 355(1):11-20. PubMed ID: 16822992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenocarcinoma of the esophagus and esophagogastric junction in patients older than 70 years: results of neoadjuvant radiochemotherapy followed by transthoracic esophagectomy.
    Camerlo A; D'Journo XB; Ouattara M; Trousse D; Doddoli C; Thomas PA
    J Visc Surg; 2012 Jun; 149(3):e203-10. PubMed ID: 22633088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery : early results and toxicity.
    Leibl BJ; Vitz S; Schäfer W; Alfrink M; Gschwendtner A; Grabenbauer GG
    Strahlenther Onkol; 2011 Apr; 187(4):231-7. PubMed ID: 21437768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach - a single-center study.
    Kuhnle PJ; Israel KF; Menges M
    Z Gastroenterol; 2019 May; 57(5):606-610. PubMed ID: 31083749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy.
    Lagarde SM; Navidi M; Gisbertz SS; van Laarhoven HW; Sumpter K; Meijer SL; Disep B; Immanuel A; Griffin SM; van Berge Henegouwen MI
    Br J Surg; 2016 Nov; 103(12):1658-1664. PubMed ID: 27696382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.